Safety and Feasibility of IRE for SRMs

PHASE2UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2019

Conditions
Kidney Cancer
Interventions
DEVICE

Irreversible Electroporation

Guided by CT and accompanied by an external spacer for fixation, needle electrodes will be placed. The amount of probes and probe placement will be attuned for specific tumour size and location, granting 15mm between the electrodes with an active tip length of 15mm. IRE pulses with pulse intensity of 1500 V/cm will be delivered in 90 consecutive pulses of 90µs.

Trial Locations (1)

1105AZ

RECRUITING

Academic Medical Center (AMC), Amsterdam

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Angiodynamics, Inc.

INDUSTRY

lead

Dr. Prof. M.P. Laguna Pes

OTHER

NCT02828709 - Safety and Feasibility of IRE for SRMs | Biotech Hunter | Biotech Hunter